Deutsche Märkte geschlossen

Grifols, S.A. (GRF.MC)

MCE - MCE Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
9,35+0,33 (+3,70%)
Börsenschluss: 05:36PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 935 712 200
https://www.grifols.com

Sektor(en)Healthcare
BrancheDrug Manufacturers - General
Vollzeitmitarbeiter23.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Thomas H. GlanzmannExecutive Chairman1,9MN/A1958
Mr. Jose Ignacio Abia BuenacheCEO & DirectorN/AN/A1968
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mr. Lluis Pons GomezSenior Vice President of Strategy & COO OfficeN/AN/A1983
Ms. Nuria Pascual LapeñaVP of Corporate Treasury, Risk Management Investor Relation & Sustainability OfficerN/AN/A1964
Mr. David Ian BellChief Corporate Development, Legal & Data Protection OfficerN/AN/A1954
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/AN/A1965
Mr. Camille AlpiChief Human Resources & Talent OfficerN/AN/A1981
Mr. Vicente Blanquer TorreChief Quality OfficerN/AN/A1961
Mr. Sergio Roura AdellPresident of Commercial Tech SupportN/AN/A1968
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 3. Die grundlegenden Scores sind Audit: 2, Vorstand: 4, Shareholderrechte: 8, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.